Caprelsa
Caprelsa ingredients
| Active ingredient | Strength |
|---|---|
| Vandetanib | 100 mg/1, 300 mg/1 |
What Caprelsa is used for
The FDA lists the approved uses on the official label (below). In the EU, vandetanib is approved as Caprelsa for:
Caprelsa is indicated for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. Caprelsa is indicated in adults, children and adolescents aged 5 years and older. For patients in whom re-arranged-during-transfection(RET) mutation is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Caprelsa
- Generic name
- Vandetanib
- Made by
- Genzyme Corporation
- Forms
- Tablet, Film Coated
- Given
- Oral
- Drug class
- Kinase Inhibitor
- FDA approval
- New drug application (NDA) NDA022405
- On the US market since
- 2011
Official information
- MedlinePlus drug information (search for Vandetanib)
In India
- Vandetanib: 1 brand in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Caprelsa?
Caprelsa (Vandetanib) is a cancer medicine made by Genzyme Corporation, approved by the US FDA.
What are the ingredients of Caprelsa?
Caprelsa contains Vandetanib (100 mg/1, 300 mg/1).
Is Caprelsa approved in Europe?
The same active substance is approved in the EU as Caprelsa.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA